What’s New for 2026?

New Targets, Modalities & Indications: Discover What's New at the 10th Complement-Based Drug Development Summit

As the complement therapeutics field enters a new era of clinical validation and commercial opportunity, the 10th Complement-Based Drug Development Summit returns with expanded content designed to help developers navigate the evolving scientific and strategic challenges facing the industry. With growing investment, advancing late-stage programs, and increased competition across targets, modalities, and indications, 2026 is set to be a pivotal year for complement innovation.

This year's agenda brings together biotech innovators, pharma leaders, and academic pioneers to explore the opportunities shaping the next generation of complement-based therapies.

Expanding Beyond Traditional Complement Targets

As the industry looks beyond established C3 and C5 approaches, developers are increasingly focused on uncovering novel mechanisms that can deliver greater differentiation and improved patient outcomes. This year's summit features expanded discussions on emerging targets including Factor B, Factor H, C1q and intracellular complement pathways, helping attendees evaluate new opportunities across the complement cascade.

Through scientific presentations and strategic discussions, gain insights into:

Identifying high-potential complement targets
Understanding emerging complement biology
Differentiating programs in an increasingly competitive landscape
Advancing first- and best-in-class therapeutic strategies

Applying Complement Science Across New Disease Areas

With clinical success already demonstrated in nephrology, complement therapies are now being explored across a wider range of indications than ever before. The 2026 meeting reflects this growing opportunity with expanded coverage of ocular, neurodegenerative, autoimmune, haematological and oncology applications.

Learn how leading organizations are:

Selecting the most promising indications for development
Translating complement biology into new therapeutic areas
Evaluating opportunities beyond rare disease settings
Building clinical strategies tailored to diverse patient populations

By bringing together experts working across multiple disease areas, attendees will gain a broader perspective on where complement therapeutics can create the greatest impact in the years ahead.

Benchmarking the Next Generation of Complement Modalities

The complement landscape continues to diversify, with developers pursuing a growing range of therapeutic approaches to improve efficacy, durability, tolerability and patient convenience. To reflect this evolution, the 2026 program offers deeper coverage of cutting-edge modalities, including siRNA, gene therapies, biologics, small molecules and novel delivery technologies.

Attendees will have the opportunity to:

Compare the advantages and limitations of different modality platforms
Discover innovative approaches to target engagement and delivery
Understand emerging strategies to enhance treatment durability
Benchmark development approaches from industry leaders

With fresh perspectives from established leaders and emerging innovators, the summit provides a unique opportunity to evaluate the technologies shaping the future of complement drug development.

Navigating the Path to Clinical and Commercial Success

As more complement programs advance into the clinic and toward commercialization, developers face increasing pressure to optimize trial design, demonstrate meaningful differentiation, and maximize the value of their therapeutic assets. Recent industry milestones have highlighted the growing momentum across the field and the importance of robust development strategies.

New discussions in 2026 will focus on:

Biomarker-driven development strategies
Improving target engagement and translational success
Optimizing clinical trial design
Prioritizing indications for maximum commercial impact
Building differentiated pipelines in a competitive market

These sessions are designed to equip attendees with practical insights that can help de-risk development and accelerate the progression of complement-based therapies.